8-K - Rhythm Pharmaceuticals, Inc. | StockGist

Current Report Details

Event Type

Regulation Fd

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

. Regulation FD Disclosure. On March 1, 2026, Rhythm Pharmaceuticals, Inc. (“Rhythm”) issued a press release announcing additional data from its global Phase 3

Regulation Fd

8.01

. Other Events. On March 1, 2026, Rhythm announced additional data from its global Phase 3 TRANSCEND trial of setmelanotide in patients with acquired hypothalam

Other Event

9.01

. Financial Statements and Exhibits. (d) Exhibits The following Exhibit 99.1 shall be deemed to be furnished and not filed. Exhibit No. Description 99.1 Press r

Exhibits Only

Exhibits (2)

8-K

FORM 8-K

99.1

EXHIBIT 99.1